GO
Loading...

Pharmaceuticals

More

  • "Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.

  • Eli Lilly Prez: EPS Will Soar 'Til 2011 Tuesday, 29 Jan 2008 | 11:50 AM ET

    Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.

  • Lilly & Amylin's Byetta Ad Buys Don't Pay Off Tuesday, 29 Jan 2008 | 10:27 AM ET
    Byetta Needle

    Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.

  • Lilly Profit Rises on Demand for Newer Drugs Tuesday, 29 Jan 2008 | 9:24 AM ET

    Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.

  • In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.

  • A $4 billion company I've never covered before, Inverness Medical Innovations, is making news this morning with a $900 million acquisition of another company I've never covered--Matria Healthcare, Inc. But that's not why I'm blogging about Inverness.

  • FDA Speaks on Merck & Schering's Vytorin Friday, 25 Jan 2008 | 6:59 PM ET

    I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...

  • In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.

  • AMGEN

    I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.

  • Amgen Profit Up on Anermia Drug Sales Thursday, 24 Jan 2008 | 4:45 PM ET

    Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.

  • Merck And Schering Reeling From Vytorin Study Thursday, 24 Jan 2008 | 1:56 PM ET

    ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.

  • Pfizer's Earnings: Reviews Are In, But Thumbs Up Or Down? Thursday, 24 Jan 2008 | 12:22 PM ET

    After yesterday's beat and boost by drug giant Pfizer and a late-day rally in the stock, analysts are providing clients their take on the numbers as the shares traded lower in the early going. Deutsche Bank's Barbara Ryan is keeping her long-standing "Buy" rating on PFE, even though she told me recently she's been "long and wrong" on the stock.

  • Ladies' Night Web Extra: Part 1 Wednesday, 23 Jan 2008 | 2:24 PM ET

    The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Pfizer Doing Its "Best" To Help Dow And Pharma Sector Wednesday, 23 Jan 2008 | 11:27 AM ET

    As I write this at the start of the second hour of regular trading, Pfizer is hangin' on to a small gain. It's the only big pharma stock trading higher this morning and for a moment after the opening bell it was the only Dow component in the green. (Merck and Schering-Plough, still reeling from the Vytorin/Zetia study, are getting pummeled again in the early going--each down more than a buck.)

  • Pfizer Tops Views; Shares Pressured by Sector Selloff Wednesday, 23 Jan 2008 | 10:12 AM ET
    Lipitor

    Pfizer Wednesday reported a higher-than-expected fourth-quarter profit, helped by lower taxes, a weak dollar and growing demand for its drugs for nerve pain, kidney cancer and smoking cession.

  • This press release and letters to the CEOs of MRK and SGP from the House Energy and Commerce Committee just arrived in my inbox:

  • Merck, SGP Go On A Vytorin "Offensive" Tuesday, 22 Jan 2008 | 11:22 AM ET

    I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.

  • Roche Wins Ventana with Raised $3.4 Billion Bid Tuesday, 22 Jan 2008 | 3:31 AM ET

    Roche Holding has overcome Ventana's resistance to its takeover bid by raising its price, acquiring the diagnostics maker for $3.4 billion to boost its cancer testing business.

  • Dendreon's Provenge: No Congressional Decision-YET Friday, 18 Jan 2008 | 4:04 PM ET

    I blogged recently that a spokesperson for the House Energy and Commerce Committee had told me a decision could be made by the end of this week regarding the Dendreon saga.

  • SGP's CEO Hassan: Putting Money Where His Mouth Is Friday, 18 Jan 2008 | 12:58 PM ET

    After watching his stock lose more than one-fifth of its value this week, Schering-Plough CEO Fred Hassan apparently decided the shares are on sale. This morning the company issued a press release announcing Hassan (pronounced Haa-sun, not the commonly mispronounced Huh-sahn) will shell out $2 million of his own money to buy SGP shares on the open market.